Robert J. Coury
Executive Chairman
After leading the transformation of Mylan into one of the world's largest global pharmaceutical companies, Robert J. Coury again led the company to another level by combining forces with Upjohn to form Viatris, a new champion for global health. His strategic vision and leadership guide the company's performance and growth.
Scott A. Smith
Chief Executive Officer
Viatris chief executive officer Scott A. Smith is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. He is a seasoned builder who possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations. Before becoming Viatris’ CEO, Smith was President of BioAtla, Inc., a global biotechnology company focused on the development of Conditionally Active BiologicsTM (CAB) antibody therapeutics and was President and Chief Operating Officer of Celgene Corp. Scott is a member of Viatris board of directors.
Rajiv Malik
President
Rajiv Malik began his pharmaceuticals career as a scientist and went on to become a leading pharmaceutical industry executive with more than 60 process patents to his name. His deep commercial, scientific and operational experience is an invaluable asset in his role as president of Viatris.
Sanjeev Narula
Chief Financial Officer
Sanjeev Narula was appointed as the chief financial officer of Viatris following 16 years of experience in senior financial leadership positions at Pfizer. He has a deep understanding of financial and commercial dynamics across geographies and in all Viatris markets.
